News 2011 › 2011-01-17
Biotie and Synosia to join forces
Biotie Therapies Corp. and Synosia Therapeutics Holding AG have announced they intend to merge to create a new force in the pharmaceuticals field, with a pipeline of nine clinical-stage drug candidates for diseases with a high unmet medical need and operations in Finland, the US, and Switzerland.
The combined clinical development pipeline includes nalmefene, Biotie's Phase 3 product candidate for the treatment of alcohol dependency. This recently reported positive results from the first two Phase 3 trials conducted by Biotie’s partner, Lundbeck, and is on track for submission for approval in Europe in the second half of 2011.
Synosia brings a broad range of innovative central nervous system (CNS) product candidates, together with a recently announced partnership with UCB Pharma SA. The latter covers SYN-115, a novel adenosine A2a receptor antagonist for Parkinson's disease in Phase 2, and SYN-118, a potential first-in-class hydroxyphenyl-pyruvate dioxygenase (HPPD) inhibitor intended for movement disorders, which is also in Phase 2.
Biotie focuses on central nervous system and inflammatory diseases, and has several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential, including addiction and a broad range of inflammatory conditions, including rheumatoid arthritis and chronic obstructive pulmonary disease (COPD).
Synosia Therapeutics, for its part, has concentrated on developing and commercialising innovative and clinically differentiated products for neurodegenerative and psychiatric disorders. The development of SYN-115 and SYN-118 for Parkinson's disease, and SYN-120 for the treatment of cognitive disorders associated with Alzheimer's and schizophrenia, are currently the main focus of activities.